Search

Your search keyword '"Hoffmann, H. J."' showing total 25 results
Start Over Author "Hoffmann, H. J." Database OAIster
25 results on '"Hoffmann, H. J."'

1. EAACI task force report: A consensus protocol for the basophil activation test for collaboration and external quality assurance

Author

CTI Research, MS Dermatologie/Allergologie, Infection & Immunity, Pascal, M, Edelman, S M, Nopp, A, Möbs, C, Geilenkeuser, W J, Knol, E F, Ebo, D G, Mertens, C, Shamji, M H, Santos, A F, Patil, S, Eberlein, B, Mayorga, C, Hoffmann, H J, CTI Research, MS Dermatologie/Allergologie, Infection & Immunity, Pascal, M, Edelman, S M, Nopp, A, Möbs, C, Geilenkeuser, W J, Knol, E F, Ebo, D G, Mertens, C, Shamji, M H, Santos, A F, Patil, S, Eberlein, B, Mayorga, C, and Hoffmann, H J

Published
2024

2. Flow-based basophil activation test in immediate drug hypersensitivity. An EAACI task force position paper

Author

Mayorga, C., Çelik, G. E., Pascal, M., Hoffmann, H. J., Eberlein, B., Torres, M. J., Brockow, K., Garvey, L. H., Barbaud, A., Madrigal-Burgaleta, R., Caubet, J. C., Ebo, D. G., Mayorga, C., Çelik, G. E., Pascal, M., Hoffmann, H. J., Eberlein, B., Torres, M. J., Brockow, K., Garvey, L. H., Barbaud, A., Madrigal-Burgaleta, R., Caubet, J. C., and Ebo, D. G.

Abstract

Diagnosing immediate drug hypersensitivity reactions (IDHRs) can pose a significant challenge and there is an urgent need for safe and reliable tests. Evidence has emerged that the basophil activation test (BAT), an in vitro assay that mirrors the in vivo response, can be a complementary test for many drugs. In this position paper, members of Task Force (TF) “Basophil activation test in the evaluation of Drug Hypersensitivity Reactions” from the European Academy of Allergy and Clinical Immunology (EAACI) present the data from a survey about the use and utility of BAT in IDHRs in Europe. The survey results indicate that there is a great interest for using BAT especially for diagnosing IDHRs. However, there are still main needs, mainly in the standardization of the protocols. Subsequently consensus-based recommendations were formulated for: (i) Technical aspects of BAT in IDHRs including type of sample, management of drugs, flow cytometry protocols, interpretation of the results; and (ii) Drug-specific aspects that should be taken into account when performing BAT in relation to betalactams, neuromuscular blocking agents, fluoroquinolones, chlorhexidine, opioids, radio contrast media, chemotherapeutics, biological agents, nonsteroidal anti-inflammatory drugs, COVID vaccine, and excipients. Moreover, aspects in the evaluation of pediatric population have also been considered. All this indicates that BAT offers the clinician and laboratory a complementary tool for a safe diagnostic for IDHRs, although its place in the diagnostic algorithm depends on the drug class and patient population (phenotype, geography, and age). The standardization of BAT is important for generalizing this method beyond the individual laboratory., Diagnosing immediate drug hypersensitivity reactions (IDHRs) can pose a significant challenge and there is an urgent need for safe and reliable tests. Evidence has emerged that the basophil activation test (BAT), an in vitro assay that mirrors the in vivo response, can be a complementary test for many drugs. In this position paper, members of Task Force (TF) “Basophil activation test in the evaluation of Drug Hypersensitivity Reactions” from the European Academy of Allergy and Clinical Immunology (EAACI) present the data from a survey about the use and utility of BAT in IDHRs in Europe. The survey results indicate that there is a great interest for using BAT especially for diagnosing IDHRs. However, there are still main needs, mainly in the standardization of the protocols. Subsequently consensus-based recommendations were formulated for: (i) Technical aspects of BAT in IDHRs including type of sample, management of drugs, flow cytometry protocols, interpretation of the results; and (ii) Drug-specific aspects that should be taken into account when performing BAT in relation to betalactams, neuromuscular blocking agents, fluoroquinolones, chlorhexidine, opioids, radio contrast media, chemotherapeutics, biological agents, nonsteroidal anti-inflammatory drugs, COVID vaccine, and excipients. Moreover, aspects in the evaluation of pediatric population have also been considered. All this indicates that BAT offers the clinician and laboratory a complementary tool for a safe diagnostic for IDHRs, although its place in the diagnostic algorithm depends on the drug class and patient population (phenotype, geography, and age). The standardization of BAT is important for generalizing this method beyond the individual laboratory.

Published
2024

3. Flow-based basophil activation test in immediate drug hypersensitivity. An EAACI task force position paper

Author

Mayorga, C., Çelik, G. E., Pascal, M., Hoffmann, H. J., Eberlein, B., Torres, M. J., Brockow, K., Garvey, L. H., Barbaud, A., Madrigal-Burgaleta, R., Caubet, J. C., Ebo, D. G., Mayorga, C., Çelik, G. E., Pascal, M., Hoffmann, H. J., Eberlein, B., Torres, M. J., Brockow, K., Garvey, L. H., Barbaud, A., Madrigal-Burgaleta, R., Caubet, J. C., and Ebo, D. G.

Abstract

Diagnosing immediate drug hypersensitivity reactions (IDHRs) can pose a significant challenge and there is an urgent need for safe and reliable tests. Evidence has emerged that the basophil activation test (BAT), an in vitro assay that mirrors the in vivo response, can be a complementary test for many drugs. In this position paper, members of Task Force (TF) “Basophil activation test in the evaluation of Drug Hypersensitivity Reactions” from the European Academy of Allergy and Clinical Immunology (EAACI) present the data from a survey about the use and utility of BAT in IDHRs in Europe. The survey results indicate that there is a great interest for using BAT especially for diagnosing IDHRs. However, there are still main needs, mainly in the standardization of the protocols. Subsequently consensus-based recommendations were formulated for: (i) Technical aspects of BAT in IDHRs including type of sample, management of drugs, flow cytometry protocols, interpretation of the results; and (ii) Drug-specific aspects that should be taken into account when performing BAT in relation to betalactams, neuromuscular blocking agents, fluoroquinolones, chlorhexidine, opioids, radio contrast media, chemotherapeutics, biological agents, nonsteroidal anti-inflammatory drugs, COVID vaccine, and excipients. Moreover, aspects in the evaluation of pediatric population have also been considered. All this indicates that BAT offers the clinician and laboratory a complementary tool for a safe diagnostic for IDHRs, although its place in the diagnostic algorithm depends on the drug class and patient population (phenotype, geography, and age). The standardization of BAT is important for generalizing this method beyond the individual laboratory., Diagnosing immediate drug hypersensitivity reactions (IDHRs) can pose a significant challenge and there is an urgent need for safe and reliable tests. Evidence has emerged that the basophil activation test (BAT), an in vitro assay that mirrors the in vivo response, can be a complementary test for many drugs. In this position paper, members of Task Force (TF) “Basophil activation test in the evaluation of Drug Hypersensitivity Reactions” from the European Academy of Allergy and Clinical Immunology (EAACI) present the data from a survey about the use and utility of BAT in IDHRs in Europe. The survey results indicate that there is a great interest for using BAT especially for diagnosing IDHRs. However, there are still main needs, mainly in the standardization of the protocols. Subsequently consensus-based recommendations were formulated for: (i) Technical aspects of BAT in IDHRs including type of sample, management of drugs, flow cytometry protocols, interpretation of the results; and (ii) Drug-specific aspects that should be taken into account when performing BAT in relation to betalactams, neuromuscular blocking agents, fluoroquinolones, chlorhexidine, opioids, radio contrast media, chemotherapeutics, biological agents, nonsteroidal anti-inflammatory drugs, COVID vaccine, and excipients. Moreover, aspects in the evaluation of pediatric population have also been considered. All this indicates that BAT offers the clinician and laboratory a complementary tool for a safe diagnostic for IDHRs, although its place in the diagnostic algorithm depends on the drug class and patient population (phenotype, geography, and age). The standardization of BAT is important for generalizing this method beyond the individual laboratory.

Published
2024

4. EUFOREA summit in Brussels 2023: inspiring the future of allergy & respiratory care

Author

Hellings, P W, Lau, S, Scadding, G K, Bjermer, L, Backer, V, Chaker, A M, Conti, D M, De Corso, E, Diamant, Z, Djukanovic, R, Fokkens, W, Gevaert, P, Gray, C L, Han, J K, Heaney, L G, Hoffmann, H J, Jesenak, M, Johansen, Pål; https://orcid.org/0000-0002-5055-6299, Kumaran, M S, McDonald, M, Melén, E, Mullol, J, Reitsma, S, Ryan, D, Scadding, G, Schmid-Grendelmeier, Peter; https://orcid.org/0000-0003-3215-3370, Teeling, T, Odemyr, M, Wahn, U, Hellings, P W, Lau, S, Scadding, G K, Bjermer, L, Backer, V, Chaker, A M, Conti, D M, De Corso, E, Diamant, Z, Djukanovic, R, Fokkens, W, Gevaert, P, Gray, C L, Han, J K, Heaney, L G, Hoffmann, H J, Jesenak, M, Johansen, Pål; https://orcid.org/0000-0002-5055-6299, Kumaran, M S, McDonald, M, Melén, E, Mullol, J, Reitsma, S, Ryan, D, Scadding, G, Schmid-Grendelmeier, Peter; https://orcid.org/0000-0003-3215-3370, Teeling, T, Odemyr, M, and Wahn, U

Abstract

In March 2023, the European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) organized its bi-annual Summit in Brussels with expert panel members of EUFOREA, representatives of the EUFOREA patient advisory board, and the EUFOREA board and management teams. Its aim was to define the research, educational and advocacy initiatives to be developed by EUFOREA over the next 2 years until the 10th anniversary in 2025. EUFOREA is an international non-for-profit organization forming an alliance of all stakeholders dedicated to reducing the prevalence and burden of chronic allergic and respiratory diseases via research, education, and advocacy. Based on its medical scientific core competency, EUFOREA offers an evidence-supported platform to introduce innovation and education in healthcare leading to optimal patient care, bridging the gap between latest scientific evidence and daily practice. Aligned with the mission of improving health care, the expert panels of asthma, allergic rhinitis (AR), chronic rhinosinusitis (CRS) & European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS), allergen immunotherapy (AIT) and paediatrics have proposed and elaborated a variety of activities that correspond to major unmet needs in the allergy and respiratory field. The current report provides a concise overview of the achievements, ambitions, and action plan of EUFOREA for the future, allowing all stakeholders in the allergy and respiratory field to be up-dated and inspired to join forces in Europe and beyond.

Published
2023

5. In-vivo diagnostic test allergens in Europe: A call to action and proposal for recovery plan - An EAACI position paper

Author

Klimek, L, Hoffmann, H J, Kalpaklioglu, A F, Demoly, P, Agache, L, Popov, T, Muraro, A, Schmid-Grendelmeier, P, Bonini, S, Bonertz, A, Mahler, V, Vieths, S, Pfaar, O, Zuberbier, T, Jutel, M, Schmidt-Weber, C, Hellings, P, Dreborg, S, Bonini, Matteo, Brough, H A, Bousquet, J, Hoffmann-Sommergruber, K, Palomares, O, Ollert, M, Shamji, M H, Cardona, V, Bonini, M (ORCID:0000-0002-3042-0765), Klimek, L, Hoffmann, H J, Kalpaklioglu, A F, Demoly, P, Agache, L, Popov, T, Muraro, A, Schmid-Grendelmeier, P, Bonini, S, Bonertz, A, Mahler, V, Vieths, S, Pfaar, O, Zuberbier, T, Jutel, M, Schmidt-Weber, C, Hellings, P, Dreborg, S, Bonini, Matteo, Brough, H A, Bousquet, J, Hoffmann-Sommergruber, K, Palomares, O, Ollert, M, Shamji, M H, Cardona, V, and Bonini, M (ORCID:0000-0002-3042-0765)

Published
2020

6. Allergic bronchopulmonary aspergillosis (ABPA)

Author

Matricardi, P M, Kleine-Tebbe, J, Hoffmann, H J, Valenta, R, Ollert, M, Matricardi, P M ( P M ), Kleine-Tebbe, J ( J ), Hoffmann, H J ( H J ), Valenta, R ( R ), Ollert, M ( M ), Crameri, R, Matricardi, P M, Kleine-Tebbe, J, Hoffmann, H J, Valenta, R, Ollert, M, Matricardi, P M ( P M ), Kleine-Tebbe, J ( J ), Hoffmann, H J ( H J ), Valenta, R ( R ), Ollert, M ( M ), and Crameri, R

Published
2016

7. Role of microbial allergens in atopic dermatitis

Author

Matricardi, P M, Kleine-Tebbe, J, Hoffmann, H J, Valenta, R, Ollert, M, Matricardi, P M ( P M ), Kleine-Tebbe, J ( J ), Hoffmann, H J ( H J ), Valenta, R ( R ), Ollert, M ( M ), Glatz, Martin, Bosshard, Philipp P, Crameri, Reto, Schmid-Grendelmeier, Peter, Matricardi, P M, Kleine-Tebbe, J, Hoffmann, H J, Valenta, R, Ollert, M, Matricardi, P M ( P M ), Kleine-Tebbe, J ( J ), Hoffmann, H J ( H J ), Valenta, R ( R ), Ollert, M ( M ), Glatz, Martin, Bosshard, Philipp P, Crameri, Reto, and Schmid-Grendelmeier, Peter

Published
2016

8. Allergic bronchopulmonary aspergillosis (ABPA)

Author

Matricardi, P M, Kleine-Tebbe, J, Hoffmann, H J, Valenta, R, Ollert, M, Matricardi, P M ( P M ), Kleine-Tebbe, J ( J ), Hoffmann, H J ( H J ), Valenta, R ( R ), Ollert, M ( M ), Crameri, R, Matricardi, P M, Kleine-Tebbe, J, Hoffmann, H J, Valenta, R, Ollert, M, Matricardi, P M ( P M ), Kleine-Tebbe, J ( J ), Hoffmann, H J ( H J ), Valenta, R ( R ), Ollert, M ( M ), and Crameri, R

Published
2016

9. Role of microbial allergens in atopic dermatitis

Author

Matricardi, P M, Kleine-Tebbe, J, Hoffmann, H J, Valenta, R, Ollert, M, Matricardi, P M ( P M ), Kleine-Tebbe, J ( J ), Hoffmann, H J ( H J ), Valenta, R ( R ), Ollert, M ( M ), Glatz, Martin, Bosshard, Philipp P, Crameri, Reto, Schmid-Grendelmeier, Peter, Matricardi, P M, Kleine-Tebbe, J, Hoffmann, H J, Valenta, R, Ollert, M, Matricardi, P M ( P M ), Kleine-Tebbe, J ( J ), Hoffmann, H J ( H J ), Valenta, R ( R ), Ollert, M ( M ), Glatz, Martin, Bosshard, Philipp P, Crameri, Reto, and Schmid-Grendelmeier, Peter

Published
2016

10. Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis

Author

Loft, N D, Skov, L, Iversen, L, Gniadecki, R, Dam, T N, Brandslund, I, Hoffmann, H J, Andersen, M R, Dessau, R B, Bergmann, A C, Andersen, N M, Andersen, P S, Bank, S, Vogel, U, Andersen, V, Loft, N D, Skov, L, Iversen, L, Gniadecki, R, Dam, T N, Brandslund, I, Hoffmann, H J, Andersen, M R, Dessau, R B, Bergmann, A C, Andersen, N M, Andersen, P S, Bank, S, Vogel, U, and Andersen, V

Abstract

Biological agents including anti-tumor necrosis factor (anti-TNF; adalimumab, infliximab, etanercept) and anti-interleukin-12/13 (IL12/23; ustekinumab) are essential for treatment of patients with severe psoriasis. However, a significant proportion of the patients do not respond to a specific treatment. Pharmacogenetics might be a way to predict treatment response. Using a candidate gene approach, 62 mainly functional single-nucleotide polymorphisms (SNPs) in 44 different genes were evaluated in 478 Danish patients with psoriasis undergoing 376 series of anti-TNF treatment and 230 series of ustekinumab treatment. Associations between genetic variants and treatment outcomes (drug survival and Psoriasis Area Severity Index reduction) were assessed using logistic regression analyses (crude and adjusted for gender, age, psoriatic arthritis and previous treatment). After correction for multiple testing controlling the false discovery rate, six SNPs (IL1B (rs1143623, rs1143627), LY96 (rs11465996), TLR2 (rs11938228, rs4696480) and TLR9 (rs352139)) were associated with response to anti-TNF treatment and 4 SNPs (IL1B (rs1143623, rs1143627), TIRAP (rs8177374) and TLR5 (rs5744174)) were associated with response to ustekinumab treatment (q<0.20). The results suggest that genetic variants related to increased IL-1β levels may be unfavorable when treating psoriasis with either anti-TNF or ustekinumab, whereas genetic variants related to high interferon-γ levels may be favorable when treating psoriasis with ustekinumab.The Pharmacogenomics Journal advance online publication, 11 July 2017; doi:10.1038/tpj.2017.31.

Published
2018

11. Current practice of allergy diagnosis and the potential impact of regulation in Europe

Author

Cardona, V., Demoly, P., Dreborg, Sten, Kalpaklioglu, A. F., Klimek, L., Muraro, A., Pfaar, O., Popov, T. A., Hoffmann, H. J., Cardona, V., Demoly, P., Dreborg, Sten, Kalpaklioglu, A. F., Klimek, L., Muraro, A., Pfaar, O., Popov, T. A., and Hoffmann, H. J.

Abstract

In the European Union (EU), the regulatory framework regarding diagnostic allergen extracts is currently in the process of being implemented at the national level. Due to these regulations, the initial and periodic renewal expenses for the registration of diagnostic allergen extracts may render extract production unprofitable. Consequently, many extracts may be at risk of removal from the market. The current survey, which was conducted by a task force of the European Academy of Allergy and Clinical Immunology, aimed to assess the current practice of allergy diagnosis in Europe. This survey revealed that skin tests continue to be the main diagnostic procedure and are used as the first option in almost two-third of all types of allergic diseases and in 90% of individuals suffering from respiratory allergies. Therefore, there is a need to ensure the availability of high-quality allergen extracts to maintain the common diagnostic procedures used by EU professionals. To reach this goal, it is necessary to align efforts and establish active partnerships between manufacturers, relevant scientific societies, consumer organizations and authorities to maintain the availability of these diagnostic tools.

Published
2018
Full Text
View/download PDF

12. EAACI Molecular Allergology User's Guide

Author

Matricardi, P. M., Kleine-Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer-Weber, B., Barber, D., Beyer, K., Biedermann, T., Bilò, M. B., Blank, S., Bohle, B., Bosshard, P. P., Breiteneder, H., Brough, H. A., Caraballo, L., Caubet, J. C., Crameri, R., Davies, J. M., Douladiris, N., Ebisawa, M., EIgenmann, P. A., Fernandez-Rivas, M., Ferreira, F., Gadermaier, G., Glatz, M., Hamilton, R. G., Hawranek, T., Hellings, P., Hoffmann-Sommergruber, K., Jakob, T., Jappe, U., Jutel, M., Kamath, S. D., Knol, E. F., Korosec, P., Kuehn, A., Lack, G., Lopata, A. L., Mäkelä, M., Morisset, M., Niederberger, V., Nowak-Węgrzyn, A. H., Papadopoulos, N. G., Pastorello, E. A., Pauli, G., Platts-Mills, T., Posa, D., Poulsen, L. K., Raulf, M., Sastre, J., Scala, E., Schmid, J. M., Schmid-Grendelmeier, P., van Hage, M., van Ree, R., Vieths, S., Weber, R., Wickman, M., Muraro, A., Ollert, M., Matricardi, P. M., Kleine-Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer-Weber, B., Barber, D., Beyer, K., Biedermann, T., Bilò, M. B., Blank, S., Bohle, B., Bosshard, P. P., Breiteneder, H., Brough, H. A., Caraballo, L., Caubet, J. C., Crameri, R., Davies, J. M., Douladiris, N., Ebisawa, M., EIgenmann, P. A., Fernandez-Rivas, M., Ferreira, F., Gadermaier, G., Glatz, M., Hamilton, R. G., Hawranek, T., Hellings, P., Hoffmann-Sommergruber, K., Jakob, T., Jappe, U., Jutel, M., Kamath, S. D., Knol, E. F., Korosec, P., Kuehn, A., Lack, G., Lopata, A. L., Mäkelä, M., Morisset, M., Niederberger, V., Nowak-Węgrzyn, A. H., Papadopoulos, N. G., Pastorello, E. A., Pauli, G., Platts-Mills, T., Posa, D., Poulsen, L. K., Raulf, M., Sastre, J., Scala, E., Schmid, J. M., Schmid-Grendelmeier, P., van Hage, M., van Ree, R., Vieths, S., Weber, R., Wickman, M., Muraro, A., and Ollert, M.

Published
2016

13. Grass pollen allergy

Author

Ollert, M, Valenta, R, Hoffmann, H J, Matricardi, P M, Kleine-Tebbe, J, Davies, Janet, Matricardi, Paolo, Schmid, Johannes, Ollert, M, Valenta, R, Hoffmann, H J, Matricardi, P M, Kleine-Tebbe, J, Davies, Janet, Matricardi, Paolo, and Schmid, Johannes

Abstract

The allergen sources Grasses are ubiquitous throughout the entire world. In places with a temperate climate, members of the Pooideae subfamily (1) like Timothy grass (Phleum pratense), Orchard grass (Dactylis glomerata), Perennial ryegrass (Lolium perenne), and bluegrass (Poa pratensis) are the most common pollen sources. The pollen of this Pooideae subfamily shows extensive IgE cross-reactivity. Grasses have a pollinating season from May to August in Central Europe, peaking in June...

Published
2016

14. Weed pollen allergy

Author

Ollert, M, Valenta, R, Hoffmann, H J, Matricardi, P M, Kleine-Tebbe, J, Gadermaier, Gabriele, Davies, Janet, Hawranek, Thomas, Weber, Richard, Ollert, M, Valenta, R, Hoffmann, H J, Matricardi, P M, Kleine-Tebbe, J, Gadermaier, Gabriele, Davies, Janet, Hawranek, Thomas, and Weber, Richard

Abstract

The term weed does not constitute a botanical family, but rather refers to diverse plants used sometimes as culinary culinary and medicinal herbs, that are ecologically adaptive and invasive segetal plants. Pollen of weeds mediating IgE-related allergic reactions are found in monocot (Poaceae) and dicot (Asteraceae, Urticaceae, Plantaginaceae, Euphorbiaceae, and Amaranthaceae) plant families(1). This section will focus on dicot weeds...

Published
2016

15. EAACI Molecular Allergology User's Guide

Author

Matricardi, P. M., Kleine-Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer-Weber, B., Barber, D., Beyer, K., Biedermann, T., Bilò, M. B., Blank, S., Bohle, B., Bosshard, P. P., Breiteneder, H., Brough, H. A., Caraballo, L., Caubet, J. C., Crameri, R., Davies, J. M., Douladiris, N., Ebisawa, M., EIgenmann, P. A., Fernandez-Rivas, M., Ferreira, F., Gadermaier, G., Glatz, M., Hamilton, R. G., Hawranek, T., Hellings, P., Hoffmann-Sommergruber, K., Jakob, T., Jappe, U., Jutel, M., Kamath, S. D., Knol, E. F., Korosec, P., Kuehn, A., Lack, G., Lopata, A. L., Mäkelä, M., Morisset, M., Niederberger, V., Nowak-Węgrzyn, A. H., Papadopoulos, N. G., Pastorello, E. A., Pauli, G., Platts-Mills, T., Posa, D., Poulsen, L. K., Raulf, M., Sastre, J., Scala, E., Schmid, J. M., Schmid-Grendelmeier, P., van Hage, M., van Ree, R., Vieths, S., Weber, R., Wickman, M., Muraro, A., Ollert, M., Matricardi, P. M., Kleine-Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer-Weber, B., Barber, D., Beyer, K., Biedermann, T., Bilò, M. B., Blank, S., Bohle, B., Bosshard, P. P., Breiteneder, H., Brough, H. A., Caraballo, L., Caubet, J. C., Crameri, R., Davies, J. M., Douladiris, N., Ebisawa, M., EIgenmann, P. A., Fernandez-Rivas, M., Ferreira, F., Gadermaier, G., Glatz, M., Hamilton, R. G., Hawranek, T., Hellings, P., Hoffmann-Sommergruber, K., Jakob, T., Jappe, U., Jutel, M., Kamath, S. D., Knol, E. F., Korosec, P., Kuehn, A., Lack, G., Lopata, A. L., Mäkelä, M., Morisset, M., Niederberger, V., Nowak-Węgrzyn, A. H., Papadopoulos, N. G., Pastorello, E. A., Pauli, G., Platts-Mills, T., Posa, D., Poulsen, L. K., Raulf, M., Sastre, J., Scala, E., Schmid, J. M., Schmid-Grendelmeier, P., van Hage, M., van Ree, R., Vieths, S., Weber, R., Wickman, M., Muraro, A., and Ollert, M.

Published
2016

16. EAACI Molecular Allergology User's Guide

Author

Matricardi, P. M., Kleine-Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer-Weber, B., Barber, D., Beyer, K., Biedermann, T., Bilò, M. B., Blank, S., Bohle, B., Bosshard, P. P., Breiteneder, H., Brough, H. A., Caraballo, L., Caubet, J. C., Crameri, R., Davies, J. M., Douladiris, N., Ebisawa, M., EIgenmann, P. A., Fernandez-Rivas, M., Ferreira, F., Gadermaier, G., Glatz, M., Hamilton, R. G., Hawranek, T., Hellings, P., Hoffmann-Sommergruber, K., Jakob, T., Jappe, U., Jutel, M., Kamath, S. D., Knol, E. F., Korosec, P., Kuehn, A., Lack, G., Lopata, A. L., Mäkelä, M., Morisset, M., Niederberger, V., Nowak-Węgrzyn, A. H., Papadopoulos, N. G., Pastorello, E. A., Pauli, G., Platts-Mills, T., Posa, D., Poulsen, L. K., Raulf, M., Sastre, J., Scala, E., Schmid, J. M., Schmid-Grendelmeier, P., van Hage, M., van Ree, R., Vieths, S., Weber, R., Wickman, M., Muraro, A., Ollert, M., Matricardi, P. M., Kleine-Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer-Weber, B., Barber, D., Beyer, K., Biedermann, T., Bilò, M. B., Blank, S., Bohle, B., Bosshard, P. P., Breiteneder, H., Brough, H. A., Caraballo, L., Caubet, J. C., Crameri, R., Davies, J. M., Douladiris, N., Ebisawa, M., EIgenmann, P. A., Fernandez-Rivas, M., Ferreira, F., Gadermaier, G., Glatz, M., Hamilton, R. G., Hawranek, T., Hellings, P., Hoffmann-Sommergruber, K., Jakob, T., Jappe, U., Jutel, M., Kamath, S. D., Knol, E. F., Korosec, P., Kuehn, A., Lack, G., Lopata, A. L., Mäkelä, M., Morisset, M., Niederberger, V., Nowak-Węgrzyn, A. H., Papadopoulos, N. G., Pastorello, E. A., Pauli, G., Platts-Mills, T., Posa, D., Poulsen, L. K., Raulf, M., Sastre, J., Scala, E., Schmid, J. M., Schmid-Grendelmeier, P., van Hage, M., van Ree, R., Vieths, S., Weber, R., Wickman, M., Muraro, A., and Ollert, M.

Published
2016

17. EAACI Molecular Allergology User's Guide

Author

MS Dermatologie/Allergologie, CDL Celdiagnostiek, Infection & Immunity, Matricardi, P. M., Kleine-Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer-Weber, B., Barber, D., Beyer, K., Biedermann, T., Bilò, M. B., Blank, S., Bohle, B., Bosshard, P. P., Breiteneder, H., Brough, H. A., Caraballo, L., Caubet, J. C., Crameri, R., Davies, J. M., Douladiris, N., Ebisawa, M., EIgenmann, P. A., Fernandez-Rivas, M., Ferreira, F., Gadermaier, G., Glatz, M., Hamilton, R. G., Hawranek, T., Hellings, P., Hoffmann-Sommergruber, K., Jakob, T., Jappe, U., Jutel, M., Kamath, S. D., Knol, E. F., Korosec, P., Kuehn, A., Lack, G., Lopata, A. L., Mäkelä, M., Morisset, M., Niederberger, V., Nowak-Węgrzyn, A. H., Papadopoulos, N. G., Pastorello, E. A., Pauli, G., Platts-Mills, T., Posa, D., Poulsen, L. K., Raulf, M., Sastre, J., Scala, E., Schmid, J. M., Schmid-Grendelmeier, P., van Hage, M., van Ree, R., Vieths, S., Weber, R., Wickman, M., Muraro, A., Ollert, M., MS Dermatologie/Allergologie, CDL Celdiagnostiek, Infection & Immunity, Matricardi, P. M., Kleine-Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer-Weber, B., Barber, D., Beyer, K., Biedermann, T., Bilò, M. B., Blank, S., Bohle, B., Bosshard, P. P., Breiteneder, H., Brough, H. A., Caraballo, L., Caubet, J. C., Crameri, R., Davies, J. M., Douladiris, N., Ebisawa, M., EIgenmann, P. A., Fernandez-Rivas, M., Ferreira, F., Gadermaier, G., Glatz, M., Hamilton, R. G., Hawranek, T., Hellings, P., Hoffmann-Sommergruber, K., Jakob, T., Jappe, U., Jutel, M., Kamath, S. D., Knol, E. F., Korosec, P., Kuehn, A., Lack, G., Lopata, A. L., Mäkelä, M., Morisset, M., Niederberger, V., Nowak-Węgrzyn, A. H., Papadopoulos, N. G., Pastorello, E. A., Pauli, G., Platts-Mills, T., Posa, D., Poulsen, L. K., Raulf, M., Sastre, J., Scala, E., Schmid, J. M., Schmid-Grendelmeier, P., van Hage, M., van Ree, R., Vieths, S., Weber, R., Wickman, M., Muraro, A., and Ollert, M.

Published
2016

18. Prenatal exposure to persistent organic pollutants and offspring allergic sensitization and lung function at 20 years of age

Author

Hansen, S, Strøm, M, Olsen, S F, Dahl, R, Hoffmann, H J, Granström, C, Rytter, D, Bech, B H, Linneberg, A, Maslova, E, Kiviranta, H, Rantakokko, P, Halldorsson, T I, Hansen, S, Strøm, M, Olsen, S F, Dahl, R, Hoffmann, H J, Granström, C, Rytter, D, Bech, B H, Linneberg, A, Maslova, E, Kiviranta, H, Rantakokko, P, and Halldorsson, T I

Abstract

BACKGROUND: Prenatal exposures to persistent organic pollutants (POPs) have been associated with asthma medication use and self-reported symptoms, but associations with lung function and allergic sensitization have been minimally explored. The aim of the study was to examine the associations between prenatal exposures to POPs and allergic sensitization and lung function in 20-year-old offspring.METHODS: In a Danish cohort of 965 pregnant women established in 1988-1989, six polychlorinated biphenyl (PCB) congeners, hexachlorobenzene (HCB), and dichlorodiphenyldichloroethylene (p,p'-DDE) were quantified in archived maternal serum drawn in gestational week 30 (n = 872). Among those with available maternal exposure information, at age 20, 421 offspring attended attended a clinical examination including measurements of allergic sensitization (serum-specific IgE ≥ 0.35 kUA /L) (n = 418) and lung function [forced expiratory volume in one second (FEV1 ) and forced vital capacity (FVC)] (n = 414).RESULTS: There were no associations between maternal concentrations of POPs and offspring allergic sensitization at 20 years of age. Maternal concentrations of POPs were, however, positively associated with offspring airway obstruction (FEV1 /FVC < 75%). Compared to offspring in the first tertile of exposure, offspring in the third tertile of dioxin-like PCB exposure had an OR of 2.96 (95% CI: 1.14-7.70). Similar associations for non-dioxin-like PCBs, HCB, and p,p'-DDE were 2.68 (1.06-6.81), 2.63 (1.07, 6.46), and 2.87 (1.09, 7.57), respectively. No associations were observed with reduced lung function (FEV1 % of predicted value < 90%).CONCLUSION AND CLINICAL RELEVANCE: Our data indicate that prenatal exposure to POPs appears to be associated with airway obstruction but not allergic sensitization at 20 years of age. The findings support that chronic obstructive lung diseases may have at least part of their origins in early life.

Published
2016

19. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease

Author

Hoffmann, H. J., Santos, A. F., Mayorga, C., Nopp, A., Eberlein, B., Ferrer, M., Rouzaire, P., Ebo, D. G., Sabato, V., Sanz, M. L., Pecaric-Petkovic, T., Patil, S. U., Hausmann, O. V., Shreffler, W. G., Korosec, P., Knol, E. F., Hoffmann, H. J., Santos, A. F., Mayorga, C., Nopp, A., Eberlein, B., Ferrer, M., Rouzaire, P., Ebo, D. G., Sabato, V., Sanz, M. L., Pecaric-Petkovic, T., Patil, S. U., Hausmann, O. V., Shreffler, W. G., Korosec, P., and Knol, E. F.

Published
2015

20. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease

Author

Hoffmann, H. J., Santos, A. F., Mayorga, C., Nopp, A., Eberlein, B., Ferrer, M., Rouzaire, P., Ebo, D. G., Sabato, V., Sanz, M. L., Pecaric-Petkovic, T., Patil, S. U., Hausmann, O. V., Shreffler, W. G., Korosec, P., Knol, E. F., Hoffmann, H. J., Santos, A. F., Mayorga, C., Nopp, A., Eberlein, B., Ferrer, M., Rouzaire, P., Ebo, D. G., Sabato, V., Sanz, M. L., Pecaric-Petkovic, T., Patil, S. U., Hausmann, O. V., Shreffler, W. G., Korosec, P., and Knol, E. F.

Published
2015

21. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease

Author

Hoffmann, H. J., Santos, A. F., Mayorga, C., Nopp, A., Eberlein, B., Ferrer, M., Rouzaire, P., Ebo, D. G., Sabato, V., Sanz, M. L., Pecaric-Petkovic, T., Patil, S. U., Hausmann, O. V., Shreffler, W. G., Korosec, P., Knol, E. F., Hoffmann, H. J., Santos, A. F., Mayorga, C., Nopp, A., Eberlein, B., Ferrer, M., Rouzaire, P., Ebo, D. G., Sabato, V., Sanz, M. L., Pecaric-Petkovic, T., Patil, S. U., Hausmann, O. V., Shreffler, W. G., Korosec, P., and Knol, E. F.

Published
2015

22. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease

Author

Lab Dermatologie/Allergologie, Hoffmann, H. J., Santos, A. F., Mayorga, C., Nopp, A., Eberlein, B., Ferrer, M., Rouzaire, P., Ebo, D. G., Sabato, V., Sanz, M. L., Pecaric-Petkovic, T., Patil, S. U., Hausmann, O. V., Shreffler, W. G., Korosec, P., Knol, E. F., Lab Dermatologie/Allergologie, Hoffmann, H. J., Santos, A. F., Mayorga, C., Nopp, A., Eberlein, B., Ferrer, M., Rouzaire, P., Ebo, D. G., Sabato, V., Sanz, M. L., Pecaric-Petkovic, T., Patil, S. U., Hausmann, O. V., Shreffler, W. G., Korosec, P., and Knol, E. F.

Published
2015

23. Diagnostic test allergens used for in vivo diagnosis of allergic diseases are at risk: a european perspective

Author

Klimek, L, Hoffmann, H J, Renz, H, Demoly, P, Werfel, T, Matricardi, P M, Muraro, A, Schmid-Grendelmeier, P, Cardona, V, Papadopoulos, N G, Klimek, L, Hoffmann, H J, Renz, H, Demoly, P, Werfel, T, Matricardi, P M, Muraro, A, Schmid-Grendelmeier, P, Cardona, V, and Papadopoulos, N G

Abstract

In the European Union (EU), allergens used for diagnostic tests (TAs) are defined as medicinal products and have to be registered by national authorities. The current situation is not homogeneous. Existing authorizations need to be kept in the market in some EU states, while others need complete new authorizations requiring clinical trials, quality assurance methods, stability studies, and periodic safety update reports. Allergen manufacturers argue that offering a comprehensive panel of TAs may be economically disastrous. Expenses for initiation and maintenance of TA authorizations far exceed their related revenues and manufacturers may be forced to significantly limit their allergen portfolios. The availability of a wide range of high-quality TAs is very important for in vivo diagnoses of IgE-mediated allergies. Increased regulatory demands induce costs that need to be covered by public health organizations or reimbursed by health insurance companies.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results